

March 5, 2018



## Syros to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company pioneering the development of medicines to control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will present a corporate overview at upcoming investor conferences. Details are as follows:

### **Cowen and Company 38<sup>th</sup> Annual Health Care Conference**

Date: Monday, March 12

Time: 12:00 p.m. ET

Location: The Boston Marriott Copley Place, 110 Huntington Avenue, Boston, MA

### **Oppenheimer 28<sup>th</sup> Annual Healthcare Conference**

Date: Wednesday, March 21

Presentation Time: 2:10 p.m. ET

Location: The Westin New York Grand Central, 212 East 42<sup>nd</sup> Street, New York, NY

A live webcast of each presentation will be available on the Investors & Media section of the Syros website at [www.syros.com](http://www.syros.com). An archived replay of the webcast will be available for approximately 30 days following each presentation.

### **About Syros Pharmaceuticals**

Syros is pioneering the understanding of the non-coding region of the genome to advance a new wave of medicines that control expression of genes. Syros has built a proprietary platform that is designed to systematically and efficiently analyze this unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. Because gene expression is fundamental to the function of all cells, Syros' gene control platform has broad potential to create medicines that achieve profound and durable benefit across a range of diseases. Syros is currently focused on cancer and monogenic diseases and is advancing a growing pipeline of gene control medicines. Syros' lead drug candidates are SY-1425, a selective RAR $\alpha$  agonist in a Phase 2 clinical trial for genomically defined subsets of patients with acute myeloid leukemia and myelodysplastic syndrome, and SY-1365, a selective CDK7 inhibitor in a Phase 1 clinical trial for patients with advanced solid tumors. Led by a team with deep experience in drug discovery, development and commercialization, Syros is located in Cambridge, Mass.

View source version on businesswire.com:

<http://www.businesswire.com/news/home/20180305005660/en/>

### **Media Contact:**

Syros Pharmaceuticals

Naomi Aoki, 617-283-4298

[naoki@syros.com](mailto:naoki@syros.com)

or

**Investor Contact:**

Stern Investor Relations, Inc.

Hannah Deresiewicz, 212-362-1200

[hannahd@sternir.com](mailto:hannahd@sternir.com)

Source: Syros Pharmaceuticals